An overview of vaccine development for COVID-19

Shahcheraghi, SH; Ayatollahi, J; Aljabali, AA; Shastri, MD; Shukla, SD; Chellappan, DK; Jha, NK; Anand, K; Katari, NK; Mehta, M; Satija, S; Dureja, H; Mishra, V; Almutary, AG; Alnuqaydan, AM; Charbe, N; Prasher, P; Gupta, G; Dua, K; Lotfi, M; Bakshi, HA; Tambuwala, MM

An overview of vaccine development for COVID-19

Shahcheraghi, SH Ayatollahi, J Aljabali, AA Shastri, MD Shukla, SD Chellappan, DK Jha, NK Anand, K Katari, NK Mehta, M Satija, S Dureja, H Mishra, V Almutary, AG Alnuqaydan, AM Charbe, N Prasher, P Gupta, G Dua, K

Lotfi, M Bakshi, HA Tambuwala, MM

Permalink

Publisher:: Future Science Ltd
Publication Type:: Journal Article
Citation:: Therapeutic Delivery, 2021, 12, (3), pp. 235-244
Issue Date:: 2021-02-24

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (688.99 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Shahcheraghi, SH
dc.contributor.author	Ayatollahi, J
dc.contributor.author	Aljabali, AA
dc.contributor.author	Shastri, MD
dc.contributor.author	Shukla, SD
dc.contributor.author	Chellappan, DK
dc.contributor.author	Jha, NK
dc.contributor.author	Anand, K
dc.contributor.author	Katari, NK
dc.contributor.author	Mehta, M
dc.contributor.author	Satija, S
dc.contributor.author	Dureja, H
dc.contributor.author	Mishra, V
dc.contributor.author	Almutary, AG
dc.contributor.author	Alnuqaydan, AM
dc.contributor.author	Charbe, N
dc.contributor.author	Prasher, P
dc.contributor.author	Gupta, G
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Lotfi, M
dc.contributor.author	Bakshi, HA
dc.contributor.author	Tambuwala, MM
dc.date.accessioned	2021-08-18T14:23:05Z
dc.date.available	2021-08-18T14:23:05Z
dc.date.issued	2021-02-24
dc.identifier.citation	Therapeutic Delivery, 2021, 12, (3), pp. 235-244
dc.identifier.issn	2041-5990
dc.identifier.issn	2041-6008
dc.identifier.uri	http://hdl.handle.net/10453/150158
dc.description.abstract	The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Future Science Ltd
dc.relation.ispartof	Therapeutic Delivery
dc.relation.isbasedon	10.4155/tde-2020-0129
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0903 Biomedical Engineering, 1004 Medical Biotechnology, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.mesh	Humans
dc.subject.mesh	Pandemics
dc.subject.mesh	COVID-19
dc.subject.mesh	COVID-19 Vaccines
dc.subject.mesh	COVID-19
dc.subject.mesh	COVID-19 Vaccines
dc.subject.mesh	Humans
dc.subject.mesh	Pandemics
dc.title	An overview of vaccine development for COVID-19
dc.type	Journal Article
utslib.citation.volume	12
utslib.location.activity	England
utslib.for	0903 Biomedical Engineering
utslib.for	1004 Medical Biotechnology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	open_access	*
dc.date.updated	2021-08-18T14:23:01Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	12
utslib.citation.issue	3

Abstract:

The COVID-19 pandemic continues to endanger world health and the economy. The causative SARS-CoV-2 coronavirus has a unique replication system. The end point of the COVID-19 pandemic is either herd immunity or widespread availability of an effective vaccine. Multiple candidate vaccines - peptide, virus-like particle, viral vectors (replicating and nonreplicating), nucleic acids (DNA or RNA), live attenuated virus, recombinant designed proteins and inactivated virus - are presently under various stages of expansion, and a small number of vaccine candidates have progressed into clinical phases. At the time of writing, three major pharmaceutical companies, namely Pfizer and Moderna, have their vaccines under mass production and administered to the public. This review aims to investigate the most critical vaccines developed for COVID-19 to date.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/150158